ARMO BioSciences has begun dosing patients in a Phase III clinical trial of AM0010 (PEGylated Interleukin-10) and FOLFOX combination for the treatment of advanced pancreatic cancer.

AM0010 is a long-acting form of recombinant human interleukin-10 (IL-10) currently being developed to stimulate the activation, proliferation and survival of intra-tumoural, tumour-reactive, cytotoxic CD8+ T-cells in patients.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The international, randomised Phase III trial is designed to assess the AM0010 + FOLFOX combination as a second-line therapy compared to FOLFOX alone in a total of 566 patients.

ARMO president and chief executive officer Peter Van Vlasselaer said: "Dosing the first patient in a Phase III trial is an important milestone in our effort to develop our novel immunotherapy for this very aggressive form of cancer.

"We chose pancreatic cancer for our first pivotal Phase III trial based on encouraging Phase I/Ib data with AM0010 as a single agent and in combination with FOLFOX."

"We chose pancreatic cancer for our first pivotal Phase III trial based on encouraging Phase I/Ib data with AM0010 as a single agent and in combination with FOLFOX.

See Also:

"In our clinical experience with AM0010, we observed durable clinical responses in several cancer types. Additionally, we observed systemic and intra-tumoural stimulation of CD8+ T-cell survival, expansion and cytotoxic activity."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial's primary endpoint is overall survival (OS), while secondary endpoints include progression-free survival (PFS), overall response rate (ORR) and safety.

The trial will also determine exloratory endpoints of biomarkers that may be associated with tumour response, immune activation and clinical efficacy outcomes.

AM0010 has secured orphan drug designation from the US Food and Drug Administration (FDA) and the European Commission (EC), as well as fast-track designation from FDA in combination with FOLFOX.